This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAion Therapeutic（AION）株式概要アイオン・セラピューティック社は、米国で健康とウェルネス事業に従事している。 詳細AION ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析株式の流動性は非常に低い 過去5年間で収益は年間9.1%減少しました。 マイナスの株主資本 意味のある時価総額がありません ( CA$2M )+2 さらなるリスクすべてのリスクチェックを見るAION Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW469,165 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA469,165 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.00597.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m43m2016201920222025202620282031Revenue CA$42.9mEarnings CA$6.3mAdvancedSet Fair ValueView all narrativesAion Therapeutic Inc. 競合他社Silo WellnessSymbol: CNSX:SILOMarket cap: CA$1.5mSimply Solventless ConcentratesSymbol: TSXV:HASHMarket cap: CA$5.8mGlow LifetechSymbol: CNSX:GLOWMarket cap: CA$8.7mHerbal DispatchSymbol: CNSX:HERBMarket cap: CA$4.6m価格と性能株価の高値、安値、推移の概要Aion Therapeutic過去の株価現在の株価CA$0.00552週高値CA$0.01552週安値CA$0.005ベータ-0.491ヶ月の変化0%3ヶ月変化0%1年変化-66.67%3年間の変化0%5年間の変化-95.45%IPOからの変化-98.28%最新ニュースNew Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.お知らせ • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).お知らせ • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesNew Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.お知らせ • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).お知らせ • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.お知らせ • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (87% average weekly change). Negative equity (-CA$1.9m). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$1.90m market cap, or US$1.40m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).お知らせ • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.お知らせ • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.お知らせ • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jul 01Aion Therapeutic Inc. Announces Management and Board ChangesAion Therapeutic Inc. announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022.Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jun 12Aion Therapeutic Inc. announced that it has received CAD 1.487017 million in fundingAion Therapeutic Inc. (CNSX:AION) announced that it has received a non-brokered private placement of 16,994,475 units of the company at a price of CAD 0.0875 per unit to raise gross proceeds of CAD 1,487,016.56 on June 11, 2021. Each unit consists of one common share in the capital of the company and one half of one common share purchase warrant. Each warrant will entitle the holder, on exercise thereof, to purchase one additional common share at a price of CAD 0.15 for a period of 24 months from the closing of the transaction. The company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The closing of the transaction is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. The company paid finder’s fees of CAD 20,874.24, in cash and 238,562 broker warrants. Each broker warrant entitles the holder thereof to acquire one common share at an exercise price of $0.15 per Common Share for a period of twenty-four months from the closing of the offering and subject to the acceleration provisions. All securities issued will be subject to a four-month plus one day hold period from the closing date under applicable Canadian securities laws.お知らせ • May 19Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple PathwaysApollon Formularies plc and Aion Therapeutic Inc. announced that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica"), and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a subsidiary of Aion. The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while Aion's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways. The testing occurred as a part of a Joint Testing Agreement between the parties and was authorized in accordance with Apollon Jamaica's Research & Development licence issued by the Jamaican government's Cannabis Licensing Authority (CLA). In the performance of services under the Joint Testing Agreement, each party confined its activities to those permitted by applicable law, with CLA licensed Apollon Jamaica performing medical cannabis activities and AI Pharma performing services involving functional medicinal mushrooms. Mushroom formulations containing psilocybin or psilocin, which comes from psychedelic mushrooms, were not included as a part of the joint testing. AI Pharma currently has an agreement with Apollon Jamaica to license equipment and an agreement with Doc's Place International Inc. to sublease space in order that AI Pharma can perform cultivation, research and development, processing and treatment services in Jamaica with regard to its medicinal mushrooms formulations. The companies next expect to negotiate a joint license agreement involving their formulations and intellectual property whereby AI Pharma may exclusively use Apollon Jamaica's medical cannabis formulations in their combined product lines in the US and Canada, and Apollon may exclusively use certain of Aion's medicinal (non-psilocybin) mushroom products in their combined product lines in Europe and Jamaica, where legal. This structure would allow Apollon to benefit from Aion's sales in the US and Canada, where Apollon Jamaica is unable to sell medical cannabis under current US and UK law. In both instances, medical care will be done by physicians and psychiatrists authorized to prescribe medications and treat patients.お知らせ • Mar 12Aion Therapeutic Inc. Files 4 New Patent Applications (Including for the Treatment of Human Cancers)Aion Therapeutic Inc. announced that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. These new additions increase intellectual property portfolio to a current total of 9 patent applications with more expected in the very near future.お知らせ • Feb 24+ 1 more updateAion Therapeutic Hires Winston De La Haye as Medical DirectorAion Therapeutic Inc. announced the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post- traumatic stress disorder (PTSD), and anorexia nervosa. The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Dr. De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University of the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.Executive Departure • Feb 06President James W. Thompson has left the companyOn the 2nd of February, James W. Thompson's tenure as President ended after less than a year in the role. We don't have any record of a personal shareholding under James W.'s name. A total of 3 executives have left over the last 12 months.お知らせ • Feb 04Aion Therapeutic Inc Announces Resignation of James Thompson as PresidentAion Therapeutic Inc. announced the resignation of Dr. James Thompson as President, effective February 2, 2021. Dr. Thompson tendered his resignation to accept a senior bio-medical advisor role with one of Aion Therapeutic’s institutional investors which will allow him to continue to support the development of the Company.お知らせ • Dec 24Aion Therapeutic Inc. announced that it has received CAD 1 million in fundingAion Therapeutic Inc. (CNSX:AION) announced a non-brokered private placement of 15,384,615 units at CAD 0.065 per unit for gross proceeds of CAD 1,000,000 on December 23, 2020. Each unit consists of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one share of the company at CAD 0.15 per share for twenty four months from closing. Furthermore, the company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The completion of the transaction is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the final approval of the Canadian Securities Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.お知らせ • Sep 21Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. (CNSX:AION) announced the closing of a non-brokered private placement of 9,090,907 units at a price of CAD 0.055 per unit for gross proceeds of up to CAD 499,999.885 on September 18, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company has the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period.お知らせ • Aug 07Osoyoos Cannabis Inc. announced that it has received CAD 1.010417 million in funding from Cannabis Growth Opportunity CorporationOn July 31, 2020, Osoyoos Cannabis Inc. (CNSX:OSO) closed the transaction. The company has issued 20,208,340 units for gross proceeds of CAD 1,010,417 in the transaction. The company issued 10,208,340 units for gross proceeds of CAD 510,417 in its third and final tranche.お知らせ • Jul 18Osoyoos Cannabis Inc. Auditor Raises 'Going Concern' DoubtOsoyoos Cannabis Inc. filed its Annual on Jul 10, 2020 for the period ending Apr 30, 2020. In this report its auditor, Buckley Dodds, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Jun 29Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million.Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million on June 26, 2020. As part of the consideration Osoyoos Cannabis Inc. will issue 36 million shares to 1196691 B.C. Ltd. at a deemed price of $0.07 per share. The transaction is expected to close on or around June 30, 2020.お知らせ • Jun 18Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced that it has entered into subscription agreement for non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on June 8, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. The transaction will include participation from a Canadian institutional investor. The company will raise funding in tranche, initial tranche of CAD 75,000 will be completed within 10 days and the remaining CAD 925,000 will be received in two additional equal tranches within 10 days of the company achieving mutually agreed corporate milestones. The Institutional Investor will be entitled to deduct from its commitment an amount equal to the aggregate gross proceeds.お知らせ • Jun 17Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced a non-brokered private placement of up to 20,000,000 units, at a price of CAD 0.05 per unit, for gross proceeds of up to CAD 1,000,000 on June 16, 2020. Each unit will consist of one common share of the company and one-half of one common share purchase warrant of the company. Each full warrant will entitle the holder to acquire one additional common share for a period of 24 months from the date of issuance at a price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. On the same date, the company announced that it has issued 1,500,000 units for gross proceeds of CAD 75,000 in first tranche of the transaction.株主還元AIONCA PharmaceuticalsCA 市場7D0%11.0%1.4%1Y-66.7%-10.2%31.1%株主還元を見る業界別リターン: AION過去 1 年間で-10.2 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。リターン対市場: AIONは、過去 1 年間で31.1 % のリターンを上げたCanadian市場を下回りました。価格変動Is AION's price volatile compared to industry and market?AION volatilityAION Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.0%Market Average Movement9.7%10% most volatile stocks in CA Market16.3%10% least volatile stocks in CA Market3.8%安定した株価: AIONの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のAIONのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2011n/aJohn Simmondsn/aAion Therapeutic Inc.は、米国で健康・ウェルネス事業に従事している。旧社名はOsoyoos Cannabis Inc.で、2020年8月に社名をAion Therapeutic Inc.に変更した。アイオン・セラピューティック社は2011年に法人化され、カナダのバンクーバーを拠点としている。もっと見るAion Therapeutic Inc. 基礎のまとめAion Therapeutic の収益と売上を時価総額と比較するとどうか。AION 基礎統計学時価総額CA$2.49m収益（TTM）-CA$6.65m売上高(TTM)CA$1.47m1.7xP/Sレシオ-0.4xPER（株価収益率AION は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AION 損益計算書（TTM）収益CA$1.47m売上原価CA$997.32k売上総利益CA$475.59kその他の費用CA$7.12m収益-CA$6.65m直近の収益報告Jan 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.013グロス・マージン32.29%純利益率-451.18%有利子負債／自己資本比率-60.1%AION の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/03 15:41終値2025/09/05 00:00収益2025/01/31年間収益2024/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aion Therapeutic Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.
お知らせ • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.
New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).
お知らせ • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.
Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.
お知らせ • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.
New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).
お知らせ • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.
Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.
お知らせ • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.
Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (87% average weekly change). Negative equity (-CA$1.9m). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$1.90m market cap, or US$1.40m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
お知らせ • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.
お知らせ • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.
お知らせ • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jul 01Aion Therapeutic Inc. Announces Management and Board ChangesAion Therapeutic Inc. announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022.
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jun 12Aion Therapeutic Inc. announced that it has received CAD 1.487017 million in fundingAion Therapeutic Inc. (CNSX:AION) announced that it has received a non-brokered private placement of 16,994,475 units of the company at a price of CAD 0.0875 per unit to raise gross proceeds of CAD 1,487,016.56 on June 11, 2021. Each unit consists of one common share in the capital of the company and one half of one common share purchase warrant. Each warrant will entitle the holder, on exercise thereof, to purchase one additional common share at a price of CAD 0.15 for a period of 24 months from the closing of the transaction. The company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The closing of the transaction is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. The company paid finder’s fees of CAD 20,874.24, in cash and 238,562 broker warrants. Each broker warrant entitles the holder thereof to acquire one common share at an exercise price of $0.15 per Common Share for a period of twenty-four months from the closing of the offering and subject to the acceleration provisions. All securities issued will be subject to a four-month plus one day hold period from the closing date under applicable Canadian securities laws.
お知らせ • May 19Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple PathwaysApollon Formularies plc and Aion Therapeutic Inc. announced that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica"), and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a subsidiary of Aion. The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while Aion's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways. The testing occurred as a part of a Joint Testing Agreement between the parties and was authorized in accordance with Apollon Jamaica's Research & Development licence issued by the Jamaican government's Cannabis Licensing Authority (CLA). In the performance of services under the Joint Testing Agreement, each party confined its activities to those permitted by applicable law, with CLA licensed Apollon Jamaica performing medical cannabis activities and AI Pharma performing services involving functional medicinal mushrooms. Mushroom formulations containing psilocybin or psilocin, which comes from psychedelic mushrooms, were not included as a part of the joint testing. AI Pharma currently has an agreement with Apollon Jamaica to license equipment and an agreement with Doc's Place International Inc. to sublease space in order that AI Pharma can perform cultivation, research and development, processing and treatment services in Jamaica with regard to its medicinal mushrooms formulations. The companies next expect to negotiate a joint license agreement involving their formulations and intellectual property whereby AI Pharma may exclusively use Apollon Jamaica's medical cannabis formulations in their combined product lines in the US and Canada, and Apollon may exclusively use certain of Aion's medicinal (non-psilocybin) mushroom products in their combined product lines in Europe and Jamaica, where legal. This structure would allow Apollon to benefit from Aion's sales in the US and Canada, where Apollon Jamaica is unable to sell medical cannabis under current US and UK law. In both instances, medical care will be done by physicians and psychiatrists authorized to prescribe medications and treat patients.
お知らせ • Mar 12Aion Therapeutic Inc. Files 4 New Patent Applications (Including for the Treatment of Human Cancers)Aion Therapeutic Inc. announced that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. These new additions increase intellectual property portfolio to a current total of 9 patent applications with more expected in the very near future.
お知らせ • Feb 24+ 1 more updateAion Therapeutic Hires Winston De La Haye as Medical DirectorAion Therapeutic Inc. announced the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post- traumatic stress disorder (PTSD), and anorexia nervosa. The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Dr. De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University of the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.
Executive Departure • Feb 06President James W. Thompson has left the companyOn the 2nd of February, James W. Thompson's tenure as President ended after less than a year in the role. We don't have any record of a personal shareholding under James W.'s name. A total of 3 executives have left over the last 12 months.
お知らせ • Feb 04Aion Therapeutic Inc Announces Resignation of James Thompson as PresidentAion Therapeutic Inc. announced the resignation of Dr. James Thompson as President, effective February 2, 2021. Dr. Thompson tendered his resignation to accept a senior bio-medical advisor role with one of Aion Therapeutic’s institutional investors which will allow him to continue to support the development of the Company.
お知らせ • Dec 24Aion Therapeutic Inc. announced that it has received CAD 1 million in fundingAion Therapeutic Inc. (CNSX:AION) announced a non-brokered private placement of 15,384,615 units at CAD 0.065 per unit for gross proceeds of CAD 1,000,000 on December 23, 2020. Each unit consists of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one share of the company at CAD 0.15 per share for twenty four months from closing. Furthermore, the company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The completion of the transaction is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the final approval of the Canadian Securities Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
お知らせ • Sep 21Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. (CNSX:AION) announced the closing of a non-brokered private placement of 9,090,907 units at a price of CAD 0.055 per unit for gross proceeds of up to CAD 499,999.885 on September 18, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company has the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period.
お知らせ • Aug 07Osoyoos Cannabis Inc. announced that it has received CAD 1.010417 million in funding from Cannabis Growth Opportunity CorporationOn July 31, 2020, Osoyoos Cannabis Inc. (CNSX:OSO) closed the transaction. The company has issued 20,208,340 units for gross proceeds of CAD 1,010,417 in the transaction. The company issued 10,208,340 units for gross proceeds of CAD 510,417 in its third and final tranche.
お知らせ • Jul 18Osoyoos Cannabis Inc. Auditor Raises 'Going Concern' DoubtOsoyoos Cannabis Inc. filed its Annual on Jul 10, 2020 for the period ending Apr 30, 2020. In this report its auditor, Buckley Dodds, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Jun 29Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million.Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million on June 26, 2020. As part of the consideration Osoyoos Cannabis Inc. will issue 36 million shares to 1196691 B.C. Ltd. at a deemed price of $0.07 per share. The transaction is expected to close on or around June 30, 2020.
お知らせ • Jun 18Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced that it has entered into subscription agreement for non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on June 8, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. The transaction will include participation from a Canadian institutional investor. The company will raise funding in tranche, initial tranche of CAD 75,000 will be completed within 10 days and the remaining CAD 925,000 will be received in two additional equal tranches within 10 days of the company achieving mutually agreed corporate milestones. The Institutional Investor will be entitled to deduct from its commitment an amount equal to the aggregate gross proceeds.
お知らせ • Jun 17Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced a non-brokered private placement of up to 20,000,000 units, at a price of CAD 0.05 per unit, for gross proceeds of up to CAD 1,000,000 on June 16, 2020. Each unit will consist of one common share of the company and one-half of one common share purchase warrant of the company. Each full warrant will entitle the holder to acquire one additional common share for a period of 24 months from the date of issuance at a price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. On the same date, the company announced that it has issued 1,500,000 units for gross proceeds of CAD 75,000 in first tranche of the transaction.
